# OnCo record ivosidenib (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/ivosidenib/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "ivosidenib" ;
  schema:name "Ivosidenib"@en ;
  schema:description "The first drug to block a mutant metabolic enzyme in cancer. With azacitidine it tripled survival in IDH1-mutated AML that could not take intensive chemotherapy."@en ;
  schema:url <https://onco.cc/drugs/ivosidenib/> ;
  schema:dateModified "2026-09-07"^^xsd:date ;
  schema:sameAs <https://en.wikipedia.org/wiki/Ivosidenib> ;
  owl:sameAs <http://www.wikidata.org/entity/Q27895417> ;
  schema:citation <https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Ivosidenib>, <https://www.nice.org.uk/guidance/ta948> ;
  onco:status "approved" ;
  onco:modality "Small-molecule IDH1 inhibitor" ;
  schema:alternateName "Tibsovo" ;
  onco:approval "US 2018: Relapsed/refractory IDH1-mutated AML", "US 2019: Newly diagnosed IDH1-mutated AML unfit for intensive chemotherapy", "US 2021: Previously treated IDH1-mutated cholangiocarcinoma", "US 2022: Newly diagnosed IDH1-mutated AML with azacitidine (AGILE)", "US 2023: Relapsed/refractory IDH1-mutated MDS", "UK 2024: Locally advanced or metastatic cholangiocarcinoma with an IDH1 R132 mutation after one or more systemic treatments; NICE TA948 recommended 31 January 2024 with a commercial arrangement" ;
  onco:related <https://onco.cc/biomarkers/idh1-r132/> ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/cholangiocarcinoma/>, <https://onco.cc/cancers/aml-idh/>, <https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/> ;
  onco:technologies <https://onco.cc/technologies/epigenetic-drugs/>, <https://onco.cc/technologies/kinase-inhibitors/>, <https://onco.cc/technologies/idh-inhibitors/> ;
  onco:targets <https://onco.cc/targets/idh/> ;
  onco:companies <https://onco.cc/companies/servier/> ;
  onco:terms <https://onco.cc/terms/differentiation-syndrome/>, <https://onco.cc/terms/crossover/> ;
  onco:trials <https://onco.cc/trials/agile/>, <https://onco.cc/trials/nct05876754/>, <https://onco.cc/trials/nct05907057/>, <https://onco.cc/trials/nct06127407/>, <https://onco.cc/trials/claridhy/> .